ANI Pharmaceuticals (ANIP) Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.

Is ANIP or GRFS more profitable?

Grifols has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	-1.28%	15.87%	6.88%
Grifols	N/A	N/A	N/A

Do analysts prefer ANIP or GRFS?

ANI Pharmaceuticals currently has a consensus price target of $79.75, suggesting a potential upside of 18.02%. Given ANI Pharmaceuticals' higher possible upside, research analysts plainly believe ANI Pharmaceuticals is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Do insiders & institutionals believe in ANIP or GRFS?

76.1% of ANI Pharmaceuticals shares are held by institutional investors. 12.7% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more volatility & risk, ANIP or GRFS?

ANI Pharmaceuticals has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

Does the media favor ANIP or GRFS?

In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Grifols. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 4 mentions for Grifols. ANI Pharmaceuticals' average media sentiment score of 1.25 beat Grifols' score of 1.12 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, ANIP or GRFS?

Grifols has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$614.38M	2.39	$18.78M	-$1.14	-59.28
Grifols	$7.21B	0.69	$64.20M	$1.17	6.22

Does the MarketBeat Community favor ANIP or GRFS?

ANI Pharmaceuticals received 89 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 64.46% of users gave ANI Pharmaceuticals an outperform vote while only 56.09% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
ANI Pharmaceuticals	Outperform Votes 439 64.46%	Underperform Votes 242 35.54%
Grifols	Outperform Votes 350 56.09%	Underperform Votes 274 43.91%

Summary

ANI Pharmaceuticals beats Grifols on 12 of the 18 factors compared between the two stocks.